# TLX101 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/tlx101

> TLX101, sponsored by Telix Pharmaceuticals Ltd (TLX), received a complete response letter from the FDA; the decision is dated April 27, 2025.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | TLX101 |
| Codes | TLX101 |
| Sponsor | Telix Pharmaceuticals Ltd (TLX) https://sec-api.dev/companies/tlx/catalysts |
| Indications |  |
| Modality |  |
| FDA designations | fast track, orphan, priority review |

## Timeline

### Aug 2024: NDA/BLA submission

- Status: completed. Date confidence: month.
- First seen 2025-02-24, last confirmed 2026-02-20.
- Press release filed with the SEC (EX-99) (accession 0001628280-26-009887): "In August 2024, we submitted a NDA for TLX101-Px for the characterization of progressive or recurrent glioma from treatment related changes in both adult and pediatric patients." https://www.sec.gov/Archives/edgar/data/2007191/000162828026009887/a20260220appendix4eand20.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-26-009887): "In August 2024, we submitted a NDA to the FDA for TLX101-Px for the characterization of progressive or recurrent glioma from treatment related changes in both adult and pediatric patients through the 505(b)(2) NDA regulatory pathway." https://www.sec.gov/Archives/edgar/data/2007191/000162828026009887/a20260220appendix4eand20.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-26-009887): "In August 2024, we submitted an NDA to the FDA for TLX101-Px for the characterization of progressive or recurrent glioma in both adult and pediatric patients from treatment related changes through the 505(b)(2) NDA regulatory pathway." https://www.sec.gov/Archives/edgar/data/2007191/000162828026009887/a20260220appendix4eand20.htm
- SEC Form 10-K (accession 0001628280-26-009943): "In August 2024, we submitted a NDA for TLX101-Px for the characterization of progressive or recurrent glioma from treatment related changes in both adult and pediatric patients." https://www.sec.gov/Archives/edgar/data/2007191/000162828026009943/tlx-20251231.htm
- SEC Form 10-K (accession 0001628280-26-009943): "In August 2024, we submitted a NDA to the FDA for TLX101-Px for the characterization of progressive or recurrent glioma from treatment related changes in both adult and pediatric patients through the 505(b)(2) NDA regulatory pathway." https://www.sec.gov/Archives/edgar/data/2007191/000162828026009943/tlx-20251231.htm
- SEC Form 10-K (accession 0001628280-26-009943): "In August 2024, we submitted an NDA to the FDA for TLX101-Px for the characterization of progressive or recurrent glioma in both adult and pediatric patients from treatment related changes through the 505(b)(2) NDA regulatory pathway." https://www.sec.gov/Archives/edgar/data/2007191/000162828026009943/tlx-20251231.htm
- SEC Form 10-K (accession 0001140361-25-005562): "In August 2024, we submitted an NDA for TLX101-CDx for the characterization of progressive or recurrent glioma from treatment related changes in both adult and pediatric patients." https://www.sec.gov/Archives/edgar/data/2007191/000114036125005562/ef20038762_20f.htm
- SEC Form 10-K (accession 0001140361-25-005562): "In August 2024, we submitted an NDA to the FDA for TLX101-CDx for the characterization of progressive or recurrent glioma in both adult and pediatric patients from treatment related changes through the 505(b)(2) NDA regulatory pathway." https://www.sec.gov/Archives/edgar/data/2007191/000114036125005562/ef20038762_20f.htm
- SEC Form 10-K (accession 0001140361-25-005562): "In August 2024, we submitted an NDA to the FDA for regulatory approval of TLX101-CDx as a radioactive diagnostic agent indicated for use with PET imaging for the characterization of progressive or recurrent glioma from treatment related changes in both adult and pediatric patients through the 505(b)(2) NDA regulatory pathway." https://www.sec.gov/Archives/edgar/data/2007191/000114036125005562/ef20038762_20f.htm
- SEC Form 10-K (accession 0001140361-25-005562): "In August 2024, we submitted an NDA to the FDA for" https://www.sec.gov/Archives/edgar/data/2007191/000114036125005562/ef20038762_20f.htm

### Oct 2024: PDUFA date

- Status: scheduled. Date confidence: month.
- First seen 2026-02-20, last confirmed 2026-02-20.
- SEC Form 10-K (accession 0001628280-26-009943): "In October 2024, the FDA accepted the NDA, granted priority review and assigned a PDUFA goal date of April" https://www.sec.gov/Archives/edgar/data/2007191/000162828026009943/tlx-20251231.htm

### Oct 2024: NDA/BLA acceptance

- Status: completed. Date confidence: month.
- First seen 2026-02-19, last confirmed 2026-02-19.
- Press release filed with the SEC (EX-99) (accession 0001628280-26-009887): "In October 2024, the FDA accepted the New Drug Application ("NDA"), and granted priority review and assigned a Prescription Drug User Fee Act ("PDUFA"), goal date of April 26, 2025." https://www.sec.gov/Archives/edgar/data/2007191/000162828026009887/a20260220appendix4eand20.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-26-009887): "In October 2024, the FDA accepted the NDA, granted priority review and assigned a PDUFA goal date of April 26, 2025." https://www.sec.gov/Archives/edgar/data/2007191/000162828026009887/a20260220appendix4eand20.htm

### Apr 2025: trial start

- Status: completed. Date confidence: month. Stage: 2.
- First seen 2026-02-19, last confirmed 2026-02-19.
- Press release filed with the SEC (EX-99) (accession 0001628280-26-009887): "TLX101-Tx was investigated in the recurrent setting in the investigator-initiated IPAX-Linz Phase 2 trial, which reported preliminary results in April 2025." https://www.sec.gov/Archives/edgar/data/2007191/000162828026009887/a20260220appendix4eand20.htm

### April 26, 2025: PDUFA date

- Status: completed, complete response letter. Date confidence: exact.
- First seen 2025-01-13, last confirmed 2026-02-19.
- Press release filed with the SEC (EX-99) (accession 0002007191-25-000047): "The NDA for TLX101-CDx (Pixclara®15, 18F-floretyrosine or 18F-FET), Telix's brain cancer imaging candidate, continues to progress with a PDUFA goal date of 26 April 2025." https://www.sec.gov/Archives/edgar/data/2007191/000200719125000047/q1bizupdate.htm
- Press release filed with the SEC (EX-99) (accession 0002007191-25-000007): "Brain cancer imaging, TLX101-CDx, (Pixclara®4, 18F-floretyrosine or 18F-FET): The FDA formally accepted Telix's New Drug Application (NDA), granted a Priority Review and provided a PDUFA6 goal date of 26 April 2025." https://www.sec.gov/Archives/edgar/data/2007191/000200719125000007/q4bizupdate.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-26-009887): "In October 2024, the FDA accepted the New Drug Application ("NDA"), and granted priority review and assigned a Prescription Drug User Fee Act ("PDUFA"), goal date of April 26, 2025." https://www.sec.gov/Archives/edgar/data/2007191/000162828026009887/a20260220appendix4eand20.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-26-009887): "In October 2024, the FDA accepted the NDA, granted priority review and assigned a PDUFA goal date of April 26, 2025." https://www.sec.gov/Archives/edgar/data/2007191/000162828026009887/a20260220appendix4eand20.htm
- SEC Form 10-K (accession 0001140361-25-005562): "In October 2024, the FDA accepted the NDA, granted priority review and assigned a PDUFA goal date of April 26, 2025." https://www.sec.gov/Archives/edgar/data/2007191/000114036125005562/ef20038762_20f.htm
- SEC Form 10-K (accession 0001140361-25-005562): "The application has been granted priority review and designated a PDUFA goal date of April 26, 2025, paving the way for a U.S. commercial launch in 2025." https://www.sec.gov/Archives/edgar/data/2007191/000114036125005562/ef20038762_20f.htm
- SEC Form 10-K (accession 0001140361-25-005562): "October 2024, the FDA accepted the NDA, granted priority review and assigned a PDUFA goal date of April 26, 2025." https://www.sec.gov/Archives/edgar/data/2007191/000114036125005562/ef20038762_20f.htm
- Press release filed with the SEC (EX-99) (accession 0002007191-25-000049): "Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that it has received a Complete Response Letter (CRL) from the United States (U.S.) Food and Drug Administration (FDA) for its New Drug Application (NDA) for TLX101-CDx (Floretyrosine F18 or 18F-FET, Pixclara®1), an investigational agent for the imaging of glioma, a rare and life-threatening brain cancer." https://www.sec.gov/Archives/edgar/data/2007191/000200719125000049/pixpr.htm

### April 27, 2025: complete response letter (CRL)

- Status: completed, complete response letter. Date confidence: exact.
- First seen 2025-04-29, last confirmed 2026-02-19.
- Press release filed with the SEC (EX-99) (accession 0002007191-25-000049): "Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that it has received a Complete Response Letter (CRL) from the United States (U.S.) Food and Drug Administration (FDA) for its New Drug Application (NDA) for TLX101-CDx (Floretyrosine F18 or 18F-FET, Pixclara®1), an investigational agent for the imaging of glioma, a rare and life-threatening brain cancer." https://www.sec.gov/Archives/edgar/data/2007191/000200719125000049/pixpr.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-26-009887): "Pixclara® (TLX101-Px, floretyrosine F18): Participated in a Type A meeting with the FDA to address deficiencies identified in the CRL received in April 2025 for Telix's PET imaging candidate for glioma." https://www.sec.gov/Archives/edgar/data/2007191/000162828026009887/a20260220appendix4eand20.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-26-009887): "In April 2025, the FDA issued a CRL, stating that additional confirmatory clinical evidence was required to progress the application." https://www.sec.gov/Archives/edgar/data/2007191/000162828026009887/a20260220appendix4eand20.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-26-009887): "In April 2025, the FDA issued a CRL citing the need for additional confirmatory clinical evidence to progress the application." https://www.sec.gov/Archives/edgar/data/2007191/000162828026009887/a20260220appendix4eand20.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/tlx101.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "TLX101 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/tlx101

```bibtex
@misc{secapidev_pdufa_tlx101_20261116,
  title        = {TLX101 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/tlx101}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_tlx101_20261116","title":"TLX101 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/tlx101","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
